Skip to main content
    G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $9.61
    -0.62 (-6.06%)

    Market Cap: $622.97M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Ginkgo Bioworks Holdings (DNA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Ginkgo Bioworks Holdings (DNA) to earn -$3.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $90.07M. Of 3 analysts, 0 rate the stock Buy or Strong Buy, 1 Hold and 2 Sell or Strong Sell, for a consensus of Sell. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 4.00, inside the Sell band from 3.5 up to 4.5. Sell and Strong Sell make up 67% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold133.3%
    Sell133.3%
    Strong Sell133.3%
    Consensus
    Sell
    Total analysts
    3

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 7.6%.

    Fiscal year ending Dec 31, 2026
    -$3.20
    EPS consensus, revenue $90.07M
    Fiscal year ending Dec 31, 2027
    -$2.90
    EPS consensus, revenue $96.90M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.20-$3.20 to -$3.201$90.07M$90.00M to $90.20M3
    Dec 31, 2027-$2.90-$2.90 to -$2.901$96.90M$84.70M to $115.00M3

    Quarterly Estimates

    The EPS consensus rises from -$1.27 for the quarter ending Dec 31, 2026 to -$1.05 for the quarter ending Mar 31, 2027.

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.27N/A2$23.03M$22.25M to $24.05M4
    Mar 31, 2027-$1.05-$1.05 to -$1.051$22.10M$19.70M to $24.10M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.42.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.20-$2.93-$3.20-$3.20-$3.42N/A
    Fiscal year ending Dec 31, 2027-$2.90-$3.21-$3.21-$3.21-$3.21N/A

    Frequently Asked Questions About DNA

    What is the DNA stock forecast?

    Consensus analyst estimates put Ginkgo Bioworks Holdings's EPS at -$3.20 for the fiscal year ending Dec 31, 2026, on revenue of $90.07M. The consensus rating from 3 analysts is Sell.

    How do analysts rate DNA stock?

    Of 3 analysts covering Ginkgo Bioworks Holdings, 0 rate it Strong Buy, 0 Buy, 1 Hold, 1 Sell and 1 Strong Sell, for a consensus of Sell.

    What EPS do analysts expect from DNA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.20, with estimates from -$3.20 to -$3.20 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.90, with estimates from -$2.90 to -$2.90 from 1 analyst.

    What revenue do analysts expect from Ginkgo Bioworks Holdings next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $90.07M, with estimates from $90.00M to $90.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $96.90M, with estimates from $84.70M to $115.00M.

    How many analysts cover DNA?

    3 analysts rate Ginkgo Bioworks Holdings stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.